(CS-083) Treating Infected DFU with Proprietary Topical Cream – a Case Series in The
us

60% of diabetic foot ulcers (DFUs) were reported to have infection and the treatment strategies with infected DFUs are mostly surgery and antibiotics with standard moisturizing dressing and literature has reported the incidence of wound closure at only 27.5% in 6 months and 44.5% in 12 months.
Given infection remains the leading cause of amputation, overcoming the challenges in healing infected DFUs is urgently needed. This study evaluates the efficacy of a novel topical cream with a proprietary formulation used  concurrently with systemic antibiotics in treating infected DFUs

Methods: DFUs with infection classified as Wagner II and adequate blood perfusion were eligible. Systemic antibiotics and debridement were given to the patients and the proprietary topical cream was applied twice daily by patients at home until healing or for up to 8 weeks. The wound closure and time to wound closure were observed

Results:

3 patients with Wagner Grade II DFUs had a baseline HbA1c 8.2% and mild infection. The proprietary topical cream was used when all of them were having oral antibiotics for infection control. After using the proprietary topical cream for up to 8 weeks, the wound closure occurred on all 3 patients.

Discussion:

This is the first time using the proprietary topical cream in US DFU patients with mild infection and it is worth noting that the wound closure occurrence is much earlier than the reported in the literature. The proprietary formulation was studied and noted it enables tissue repair by regulating macrophages. This provides the future treatment in infected DFUs with a novel solution to accelerate healing.